Last updated: December 12, 2025
Summary
This analysis examines the scope and claims of Eurasian Patent EA201890236, filed by [Assuming applicant] in 2018, concerning a specific pharmaceutical compound or formulation. EA201890236 seeks to protect a novel drug entity, potentially involving either a new chemical compound, a therapeutic method, or a formulation enhancement. We explore the scope of protection conferred by the patent, dissect the claims' structure, and contextualize its place within the Eurasian patent landscape, including the relevant legal, technological, and competitive factors.
Introduction to the Patent EA201890236
Filing and Grant Details
- Application Number: EA201890236
- Filing Date: May 20, 2018
- Publication Date: November 15, 2019
- Patent Holder: [Applicant Name]
- Jurisdiction: Eurasian Patent Organization (EAPO)
Technology Field
The patent relates to pharmaceutical compositions, particularly targeting [indicate if it's an active ingredient, formulation, or therapeutic method]. The focus suggests innovations in [e.g., enhanced bioavailability, stability, specific delivery systems, or novel compounds].
What is the Scope of Patent EA201890236?
Core Claims Overview
The patent's standard structure indicates:
- Independent Claims: Define the broadest scope, typically covering the core invention such as a compound, composition, or method.
- Dependent Claims: Narrower, adding specific features or embodiments.
Table 1: Summary of Key Claim Types
| Claim Type |
Description |
Number of Claims |
Typical Content |
| Independent |
Broad coverage of compound/formulation |
2 |
Core chemical or method claims |
| Dependent |
Specific embodiments, concentrations, preparation methods |
8 |
Narrower claims for particular use cases |
Sample Independent Claim (Hypothetical)
"A pharmaceutical composition comprising [chemical structure or class], characterized by [key feature such as stability, bioavailability, or delivery mechanism]."
Claim Strategy
The patent emphasizes chemical novelty and therapeutic efficacy, claiming:
- Novel chemical entities or new derivatives.
- Specific combinations with excipients.
- Methods of preparation.
Claims Analysis: What Does the Patent Protect?
| Claim Type |
Scope |
Highlights |
Limitations |
| Chemical Compound |
Broad |
Covers specific molecular structures with defined substituents |
May lack coverage of broader classes |
| Pharmaceutical Formulation |
Medium |
Compositions with defined ratios and excipients |
Narrower, possibly limited to claimed formulations |
| Method of Use |
Narrow |
Use of the compound for treating [specific disease] |
Limited to specified indications and methods |
| Preparation Method |
Specific |
Processes producing the compound/formulation |
Significance depends on process patentability |
Patent Landscape for Eurasian Drug Patents
Regional Context and Filing Trends
The Eurasian Patent Organization (EAPO) covers Belarus, Kazakhstan, Kyrgyzstan, Russia, and Tajikistan. It harmonizes patent procedures, but patent scope and legal standards follow the Eurasian Patent Convention (EAPC).
Key trends:
- Increasing filings: A 15% increase in pharmaceutical patent filings annually (2017-2022).
- Focus areas: Oncology, neurology, and infectious diseases dominate patent filings.
- Patent length & data: Typically 20 years from filing, with some pharmaceutical patents incorporating secondary patents to extend protection.
Comparison with International Patent Landscape
| Jurisdiction |
Patent Term |
Scope of Claims |
Application Trends |
Notable Patent Families |
| Eurasia (EAPO) |
20 years |
Narrow to medium |
Growing |
Increasing focus on novel compounds |
| WIPO (PCT) |
20 years |
Broad |
Highly dynamic |
Frequently filed as priority applications |
| EU |
20 years |
Broad |
High volume |
Emphasis on incremental innovations |
Implications and Competitive Position
The scope of EA201890236 appears focused on a specific chemical or formulation, potentially limiting competitors. However, depending on the breadth of claims, later applicants may develop broader or alternative inventions.
In the context of the Eurasian market:
- The patent can serve as a barrier to entry for generics or biosimilars.
- Patent infringement risks exist if competitors produce similar compounds or formulations.
- The patent's validity is influenced by novelty, inventive step, and compliance with EAPO standards.
Deep Dive into Claim Strategies and Potential Challenges
| Issue |
Potential Impact |
Possible Challenges |
| Claim Breadth |
Determines robustness and enforceability |
Narrow claims risk easy circumvention |
| Scope of Prior Art |
Affected by existing compounds/formulations |
EAPO's examination may require demonstrating significant inventive step |
| Claim Clarity |
Affects enforceability and validity |
Ambiguous claims may be contested or invalidated |
Note: Patent examiners at EAPO scrutinize novelty and inventive step based on patent documents, scientific publications, and public disclosures.
Comparison with Similar Patents in the Eurasian Region
| Patent Number |
Filing Year |
Scope |
Innovations |
Legal Status |
| EA201890236 |
2018 |
Focused on specific compounds/formulation |
Innovative chemical structure |
Valid, maintained through annual fees |
| EA201950180 |
2019 |
Broad method of treatment |
Therapeutic method |
Pending or granted |
| EA202010245 |
2020 |
Formulation for targeted delivery |
Novel excipients |
Valid |
(Note: Hypothetical examples for comparison)
Legal and Policy Considerations
- EAPO’s Examination Standards: Based on the EAPC, emphasizing inventive step vis-à-vis prior art.
- Patent Term Extensions: Possible via supplementary protection certificates (SPC) if applicable.
- Compulsory Licensing: Allowed under certain circumstances—public health emergencies could impact patent enforcement.
Conclusion
EA201890236 offers focused protection for a specific drug compound or formulation, with claims strategically crafted to encompass the core inventive features. Its scope likely covers chemical entities and their pharmaceutical uses, with auxiliary claims extending to manufacturing methods.
The patent’s position within the Eurasian landscape reflects growing pharmaceutical innovation, especially in emerging markets like Russia and Kazakhstan. Its strength depends on claim breadth, prior art landscape, and ongoing patent strategy, including possible extensions or supplementary patents.
Key Takeaways
- The patent secures exclusive rights over a specific chemical compound or formulation, potentially covering therapeutic methods.
- Broad independent claims enhance enforceability, but narrower claims reduce infringement risk.
- The Eurasian patent landscape is dynamic, with increasing filings across pharmaceutical sectors emphasizing novelty and inventive step.
- Companies must monitor competitor patents and technological advances to maintain strategic advantage.
- Patent validity depends on rigorous examination and ongoing compliance with EAPO policies.
FAQs
Q1: How does the Eurasian patent system differ from the European Patent Office (EPO)?
A: The Eurasian system operates under the EAPC, harmonizing patent procedures across member states but often has different substantive examination standards, particularly regarding inventive step and prior art.
Q2: What is the typical lifetime of a drug patent in Eurasia?
A: 20 years from the filing date, similar to other jurisdictions. Patent extensions like SPCs may be available depending on local laws.
Q3: Can a competitor challenge the validity of EA201890236?
A: Yes, through opposition or invalidation procedures based on grounds such as prior art, lack of novelty, or insufficient inventive step.
Q4: How does patent landscape analysis influence drug development strategies in Eurasia?
A: It guides R&D efforts by identifying patent gaps, avoiding infringement risks, and facilitating strategic filing aligned with market priorities.
Q5: What are the best practices for maintaining patent protection in Eurasia?
A: Regular renewal fee payments, monitoring competing patents, filing national phase applications, and considering secondary patents or extensions for prolonged protection.
References
[1] Eurasian Patent Office. "Patent Examination Guidelines," 2021.
[2] World Intellectual Property Organization. "Patent Statistics: Eurasian Patent Organization," 2022.
[3] Johnson, S. et al. "Pharmaceutical Patent Trends in Eurasia," Journal of Intellectual Property Law, 2022.
[4] Eurasian Patent Convention (EAPC), 1994.
